Ardelyx, Inc. (ARDX)

1.24
0.38 44.00
NASDAQ
Prev Close 0.86
Open 0.91
Day Low/High 0.82 / 1.31
52 Wk Low/High 0.86 / 9.23
Volume 45.29M
Exchange NASDAQ
Shares Outstanding 112.74B
Market Cap 100.62M
P/E Ratio N/A
Div & Yield N.A. (N.A)
I'm Happily Keeping My Covered Call Options Rolling, Rolling, Rolling

I'm Happily Keeping My Covered Call Options Rolling, Rolling, Rolling

The simple strategy may not make for home runs but is producing a number of singles and doubles in a dicey market.

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.

A Trifecta of Bad News Makes for a Rough Day for This Biotech Investor

A Trifecta of Bad News Makes for a Rough Day for This Biotech Investor

Shares of Cara Therapeutics, Adverum Biotechnologies and Ardelyx Inc. all took big hits after each company announced unfavorable developments.

2 Small-Caps Still Worth Considering in This Red-Hot Market

2 Small-Caps Still Worth Considering in This Red-Hot Market

Oncology concern Exelixis and biopharma Ardelyx offer reasons to believe their shares should rise in the months ahead.

These 3 Biotechs Have Decent Values

These 3 Biotechs Have Decent Values

One would need to use covered calls to initiate positions that provide a solid amount of downside protection.

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

Ardelyx Jumps on License Deal; Otonomy Rises on Otividex News -- Biotech Movers

The Fremont, Calif.-based firm and Kyowa Hakko Kirin signed a license pact for Ardelyx's lead investigational product, tenapanor.

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers

The South San Francisco, Calif.-based firm said its Phase 3 study of tirasemtiv in patients with amyotrophic lateral sclerosis did not achieve primary or secondary endpoints.

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

Abeona Shares Higher After Pricing Stock Offering -- Biotech Movers

The clinical-stage biopharmaceutical firm said Oct. 16 it has priced an underwritten public offering of five million shares at $16 apiece.

This Market Action Is Not Creating Many Setups

This Market Action Is Not Creating Many Setups

Until market conditions shift, I won't be making any sizable buys.

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

Ardelyx Soars on Positive Phase 3 Data -- Biotech Movers

The Fremont, Calif.-based firm has unveiled positive results from its second Phase 3 study of tenapanor for irritable bowel syndrome with constipation.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Ardelyx Has Big Potential

Ardelyx Has Big Potential

This small-cap company's shares are half where they ended 2015.

Profiting on Small-Cap Biotech Earnings

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.